Craig Binnie, Associate
Dr. Craig Binnie, an associate with Alba, was most recently Director of Drug Development,
Trillium Therapeutics in Toronto, a developer of novel recombinant proteins and other biologicals for a variety of clinical indications.
He has over 20 years of expertise in the design and management of new drug development programmes,
including critical evaluation of existing drug development programmes
and preparation of submissions for government assistance (e.g. IRAP).
In addition he is experienced in outsourcing and management of drug manufacturing process development,
outsourcing and management of manufacturing of Clinical Trial Materials,
design / outsourcing / management of GLP-compliant preclinical studies to support IND and CTA submissions.
In the past, he prepared documents for pre-IND, pre-CTA and IND / CTA submissions,
represented companies at regulatory agency meetings,
evaluated eligibility for Orphan Drug Status and preparation of Orphan Drug Submissions in the USA and EU,
and evaluation and selection of Clinical Research Organizations for early stage clinical trials.